BRPI0017596A2 - Método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente - Google Patents

Método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente

Info

Publication number
BRPI0017596A2
BRPI0017596A2 BRPI0017596A BRPI0017596A2 BR PI0017596 A2 BRPI0017596 A2 BR PI0017596A2 BR PI0017596 A BRPI0017596 A BR PI0017596A BR PI0017596 A2 BRPI0017596 A2 BR PI0017596A2
Authority
BR
Brazil
Prior art keywords
radiolabeling
chelator
administration
patient
antibody conjugated
Prior art date
Application number
Other languages
English (en)
Inventor
John E Leonard
Michael Labarre
Paul Chinn
Ronald Morena
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of BRPI0017596A2 publication Critical patent/BRPI0017596A2/pt
Publication of BRPI0017596B1 publication Critical patent/BRPI0017596B1/pt
Publication of BRPI0017596B8 publication Critical patent/BRPI0017596B8/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/534Production of labelled immunochemicals with radioactive label
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
BRPI0017596A 1999-03-01 2000-02-29 método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente BRPI0017596B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/259,337 US20020102208A1 (en) 1999-03-01 1999-03-01 Radiolabeling kit and binding assay
PCT/US2000/005061 WO2000052473A2 (en) 1999-03-01 2000-02-29 Radiolabeling kit and binding assay
BRPI0008719-0 BRPI0008719B8 (pt) 1999-03-01 2000-02-29 Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo

Publications (3)

Publication Number Publication Date
BRPI0017596A2 true BRPI0017596A2 (pt) 2011-09-27
BRPI0017596B1 BRPI0017596B1 (pt) 2015-09-01
BRPI0017596B8 BRPI0017596B8 (pt) 2023-04-25

Family

ID=22984524

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0008719-0 BRPI0008719B8 (pt) 1999-03-01 2000-02-29 Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo
BRPI0017596A BRPI0017596B8 (pt) 1999-03-01 2000-02-29 método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0008719-0 BRPI0008719B8 (pt) 1999-03-01 2000-02-29 Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo

Country Status (35)

Country Link
US (2) US20020102208A1 (pt)
EP (2) EP2112512B1 (pt)
JP (1) JP4704570B2 (pt)
KR (1) KR100729247B1 (pt)
CN (1) CN1235639C (pt)
AT (1) ATE433108T1 (pt)
AU (1) AU776747B2 (pt)
BG (1) BG65690B1 (pt)
BR (2) BRPI0008719B8 (pt)
CA (2) CA2742153C (pt)
CY (2) CY1109335T1 (pt)
CZ (2) CZ306959B6 (pt)
DE (1) DE60042326D1 (pt)
DK (2) DK1192463T3 (pt)
EE (1) EE05650B1 (pt)
ES (2) ES2328100T3 (pt)
HK (2) HK1045730B (pt)
HR (1) HRP20010714B1 (pt)
HU (2) HU230516B1 (pt)
IL (1) IL145109A0 (pt)
ME (1) ME00782B (pt)
MX (1) MXPA01008837A (pt)
MY (1) MY138674A (pt)
NO (2) NO329142B1 (pt)
NZ (2) NZ513788A (pt)
PL (1) PL205780B1 (pt)
PT (2) PT2112512E (pt)
RS (1) RS51778B (pt)
RU (1) RU2251110C2 (pt)
SI (2) SI1192463T1 (pt)
SK (2) SK287745B6 (pt)
TW (1) TWI294969B (pt)
UA (1) UA78484C2 (pt)
WO (1) WO2000052473A2 (pt)
ZA (1) ZA200106943B (pt)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
EP1918305A1 (en) 1999-08-11 2008-05-07 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
DE60143535D1 (de) 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
WO2002079255A1 (en) * 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
WO2003024388A2 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
ATE408712T1 (de) 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
NZ543495A (en) * 2003-06-25 2009-04-30 Peregrine Pharmaceuticals Inc Method and apparatus for continuous large-scale radiolabeling of proteins
ES2346978T3 (es) 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
EP2301575A1 (en) 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
EP1694360B1 (en) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
EP2236172A1 (en) 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
WO2005044304A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および/または炎症性成分を有する疾患の診断および治療のための方法
EP2238986A3 (en) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
EP1921982A2 (en) * 2005-08-25 2008-05-21 Koninklijke Philips Electronics N.V. 4d image-based planning methods and apparatus for targeted therapy
CN101535244B (zh) 2005-11-23 2014-07-23 文塔納医疗系统公司 分子缀合物
EA018301B1 (ru) 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
DK2089401T3 (da) * 2006-11-10 2012-09-17 Radioprotect Alphaptose Ug Haftungsbeschraenkt & Co Kg Anvendelse af trisubstituerede glycerolforbindelser til behandling af strålingsskader
CZ300074B6 (cs) * 2006-12-20 2009-01-21 Azacycles S. R. O. Inteligentní trífunkcní makrokonjugáty a farmaceutický nebo diagnostický prostredek s jejich obsahem
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
AU2008205244B2 (en) 2007-01-09 2013-02-07 Biogen Ma Inc. Sp35 antibodies and uses thereof
MX2010006395A (es) * 2007-12-21 2010-07-01 Hoffmann La Roche Formulacion de anticuerpos.
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
JP5475774B2 (ja) 2008-07-16 2014-04-16 インスティテュート フォー リサーチ イン バイオメディシン ヒトサイトメガロウイルス中和抗体およびその使用
SG10201608381SA (en) 2008-07-16 2016-11-29 Inst Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
NZ590890A (en) 2008-07-25 2013-05-31 Inst Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
CN108610416B (zh) 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
US20110212106A1 (en) 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
HUE027831T2 (en) 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for breast cancer
EP2591006B1 (en) 2010-07-09 2019-04-24 Bioverativ Therapeutics Inc. Processable single chain molecules and polypeptides made using same
EP2601214B1 (en) 2010-08-06 2017-11-01 Genzyme Corporation Vegf antagonist compositions and uses thereof
AU2011288946A1 (en) 2010-08-13 2013-03-21 Rdm Empreendimentos E Participacoes S.A. Method and composition for reducing the color of sugar
PT3045183T (pt) 2011-03-11 2018-11-02 Genzyme Corp Apelina peguilada e suas utilizações
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
EA030319B1 (ru) 2012-03-20 2018-07-31 Хумабс Биомед Са Антитела, нейтрализующие rsv, mpv и pvm, и их применения
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
RU2522203C2 (ru) * 2012-06-26 2014-07-10 Василий Александрович Ишутин Способ контроля стерилизации материалов и изделий
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
BR112015020885A2 (pt) 2013-03-11 2017-10-10 Genzyme Corp polipeptídeos de ligação hiperglicosilados
WO2014165216A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
AU2014283185B2 (en) 2013-06-21 2019-05-02 Innate Pharma Enzymatic conjugation of polypeptides
RU2558929C2 (ru) * 2013-08-08 2015-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" (НИИ Кардиологии) СПОСОБ ОПРЕДЕЛЕНИЯ СВЯЗЫВАНИЯ РАДИОФАРМПРЕПАРАТА НА ОСНОВЕ ЦИПРОФЛОКСАЦИНА, МЕЧЕННОГО 99mTc C БАКТЕРИЯМИ
PE20160244A1 (es) 2013-08-13 2016-05-10 Sanofi Sa Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
US11052177B2 (en) 2013-09-06 2021-07-06 The Trustees Of The University Of Pennsylvania Antimicrobial polymer layers
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
JP6156962B2 (ja) * 2014-02-27 2017-07-05 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム エキソソームを単離するための方法および組成物
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
TWI694086B (zh) 2014-03-27 2020-05-21 美商銳意公司 結合人類大麻素1(cb1)受體之抗體
MX2017000595A (es) 2014-07-15 2017-10-12 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
CA2964123C (en) 2014-10-09 2023-09-05 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
BR112017010298B1 (pt) 2014-11-18 2023-10-31 Humabs Biomed Sa Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, usos dos mesmos, molécula de ácido nucleico, vetor, célula isolada, composição farmacêutica, e kit de partes
US10442854B2 (en) 2015-06-01 2019-10-15 Medimmune, Llc Neutralizing anti-influenza binding molecules and uses thereof
KR20180031019A (ko) 2015-07-30 2018-03-27 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Pgd2에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 dp―2 유전자의 단일 뉴클레오티드 다형성 대립유전자
WO2017040708A1 (en) 2015-08-31 2017-03-09 Fruition Marketing, Llc Consumer usable device with redeemable member
JP7020687B2 (ja) 2015-09-15 2022-02-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム T細胞受容体(tcr)結合抗体及びその使用
MX2018003982A (es) 2015-09-30 2019-01-31 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
AU2017207330C1 (en) 2016-01-13 2022-06-09 Medimmune, Llc Method of treating influenza A
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
WO2018193063A2 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
AU2018261947A1 (en) 2017-05-05 2019-11-07 Vaccinex, Inc. Human anti-semaphorin 4D antibody
CN111032089A (zh) 2017-07-19 2020-04-17 霍夫曼技术公司 用于治疗应激相关障碍的组合物
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
RU2700584C1 (ru) * 2018-12-13 2019-09-18 Общество С Ограниченной Ответственностью "Апто-Фарм" Способ оценки сродства олигонуклеотида
LT3898668T (lt) 2018-12-19 2023-11-10 Humabs Biomed Sa Antikūnai, neutralizuojantys hepatito b virusą ir jų panaudojimas
MX2022002231A (es) 2019-08-29 2022-03-22 Vir Biotechnology Inc Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b.
CN115515643A (zh) 2020-02-28 2022-12-23 建新公司 用于优化的药物缀合的经修饰的结合多肽
AU2021286476A1 (en) 2020-06-11 2023-02-02 Vaccinex, Inc. Use of CXCL13 binding molecules to promote peripheral nerve regeneration
US20240092872A1 (en) 2021-01-26 2024-03-21 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
WO2024068944A1 (en) 2022-09-30 2024-04-04 Sanofi Anti-cd28 antibodies
WO2024089609A1 (en) 2022-10-25 2024-05-02 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) * 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) * 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
JPS5982222U (ja) * 1982-11-26 1984-06-02 松井 三郎 眼鏡
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) * 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
DK172629B1 (da) * 1986-02-14 1999-03-22 Nihon Mediphysics Co Ltd Reaktive højmolekylære forbindelser med mindst én fri aminogruppe, højmolekylære forbindelser kombineret med et fysiologisk
EP0529645B1 (en) * 1986-09-05 1996-10-23 GANSOW, Otto A. Process for the preparation of backbone polysubstituted chelates
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
AU630362B2 (en) * 1988-05-25 1992-10-29 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Macrocyclic chelates & methods of use thereof
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) * 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
JPH06501705A (ja) 1990-11-05 1994-02-24 ブリストル−マイアーズ スクイブ カンパニー 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
US5208008A (en) * 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
CA2075928A1 (en) * 1991-01-11 1992-07-12 Roger W. Hackett Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
US5403573A (en) * 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
EP0752248B1 (en) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5942210A (en) 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay

Also Published As

Publication number Publication date
PL352531A1 (en) 2003-08-25
TWI294969B (pt) 2008-03-21
ES2328100T3 (es) 2009-11-10
NZ530868A (en) 2005-12-23
HUP0202522A2 (hu) 2002-11-28
CA2742153A1 (en) 2000-09-08
DK2112512T3 (en) 2014-12-15
CA2362119C (en) 2012-12-11
AU3505200A (en) 2000-09-21
CY1116265T1 (el) 2017-02-08
CN1345417A (zh) 2002-04-17
CZ306959B6 (cs) 2017-10-11
PL205780B1 (pl) 2010-05-31
KR20020021772A (ko) 2002-03-22
DE60042326D1 (de) 2009-07-16
EE200100465A (et) 2002-10-15
HRP20010714B1 (en) 2009-01-31
DK1192463T3 (da) 2009-10-05
US20020102208A1 (en) 2002-08-01
SK12162001A3 (sk) 2002-12-03
IL145109A0 (en) 2002-06-30
CN1235639C (zh) 2006-01-11
SI1192463T1 (sl) 2009-10-31
ZA200106943B (en) 2002-11-22
HUP1300275A2 (en) 2002-11-28
HU230516B1 (hu) 2016-10-28
HU229627B1 (en) 2014-03-28
ES2526723T3 (es) 2015-01-14
UA78484C2 (en) 2007-04-10
CZ20013126A3 (cs) 2002-07-17
CA2362119A1 (en) 2000-09-08
EP1192463A2 (en) 2002-04-03
MXPA01008837A (es) 2002-05-14
JP4704570B2 (ja) 2011-06-15
WO2000052473A3 (en) 2002-01-31
NO20100717L (no) 2001-10-31
SK288096B6 (sk) 2013-07-02
CY1109335T1 (el) 2014-07-02
RS51778B (sr) 2011-12-31
PT1192463E (pt) 2009-09-10
HK1045730B (zh) 2006-08-18
EP2112512B1 (en) 2014-11-19
NO330705B1 (no) 2011-06-20
BG105957A (en) 2002-08-30
BRPI0008719B8 (pt) 2021-07-06
NO20014245L (no) 2001-10-31
BG65690B1 (bg) 2009-06-30
CA2742153C (en) 2015-04-14
EP2112512A3 (en) 2009-12-16
SK287745B6 (sk) 2011-08-04
PT2112512E (pt) 2015-01-13
ME00782B (me) 2012-03-20
NO20014245D0 (no) 2001-08-31
EP2112512A2 (en) 2009-10-28
MY138674A (en) 2009-07-31
NZ513788A (en) 2004-03-26
CZ303262B6 (cs) 2012-07-04
HRP20010714A2 (en) 2003-02-28
BRPI0017596B8 (pt) 2023-04-25
WO2000052473A2 (en) 2000-09-08
HUP0202522A3 (en) 2011-03-28
HK1131208A1 (en) 2010-01-15
YU61601A (sh) 2004-07-15
BRPI0008719A (pt) 2001-12-26
KR100729247B1 (ko) 2007-06-15
ATE433108T1 (de) 2009-06-15
JP2002538179A (ja) 2002-11-12
US7608241B2 (en) 2009-10-27
EE05650B1 (et) 2013-04-15
RU2251110C2 (ru) 2005-04-27
SI2112512T1 (sl) 2015-02-27
US20050169838A1 (en) 2005-08-04
NO329142B1 (no) 2010-08-30
BRPI0008719B1 (pt) 2015-07-21
EP1192463B1 (en) 2009-06-03
HK1045730A1 (en) 2002-12-06
WO2000052473A9 (en) 2001-03-08
AU776747B2 (en) 2004-09-23
BRPI0017596B1 (pt) 2015-09-01

Similar Documents

Publication Publication Date Title
BRPI0017596A2 (pt) Método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
BRPI9912227B8 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
CR20150350A (es) Proceso para preparar conjugados de anticuerpo y maytansinoide
BRPI0210579B8 (pt) anticorpo e composição farmacêutica
DE69937899D1 (de) Antikörper-serumprotein hybride
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
DE60041592D1 (de) Testverfahren für verbindungen die frühzeitige tra
EA202092087A1 (ru) Анализы для выявления нейродегенеративных заболеваний
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
AU5352901A (en) Method for quantification of akt protein expression
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
BR0108609A (pt) Anticorpo com especificidade pelo câncer de cólon
WO2001073031A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
ATE414904T1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2- glycoprotein-i-komplexes in vivo
이종권 et al. Evaluation of neutral red uptake and alamar blue assays using hacat cell as a screening test for skin irritancy

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/09/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/02/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2330 DE 01/09/2015 QUANTO AO PRAZO DE VALIDADE. (PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/02/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO )

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/02/2020